

Jyh-Ming Liou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6197770/publications.pdf>

Version: 2024-02-01

110
papers

3,854
citations

126708

33
h-index

143772

57
g-index

110
all docs

110
docs citations

110
times ranked

4200
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Refractory <i>Helicobacter pylori</i> Infection-Tailored or Empirical Therapy. <i>Gut and Liver</i> , 2022, 16, 8-18.	1.4	13
2	Primer for Development of Guidelines for <i>Helicobacter pylori</i> Therapy Using Antimicrobial Stewardship. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 973-983.e1.	2.4	53
3	Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. <i>Neurology</i> , 2022, 98, .	1.5	90
4	Current Status of the Spectrum and Therapeutics of <i>Helicobacter pylori</i> -Negative Mucosa-Associated Lymphoid Tissue Lymphoma. <i>Cancers</i> , 2022, 14, 1005.	1.7	11
5	Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1219-1230.	1.5	18
6	Alteration of taste or smell as a predictor of COVID-19. <i>Gut</i> , 2021, 70, 806-807.	6.1	13
7	Changes of serum pepsinogen level and ABC classification after bariatric surgery. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 1377-1385.	0.8	9
8	Bismuth salts with versus without acid suppression for <i>Helicobacter pylori</i> infection: A transmission electron microscope study. <i>Helicobacter</i> , 2021, 26, e12801.	1.6	9
9	The interplay between <i>Helicobacter pylori</i> and gastrointestinal microbiota. <i>Gut Microbes</i> , 2021, 13, 1-22.	4.3	79
10	The efficacy of <i>Lactobacillus acidophilus</i> and <i>rhamnosus</i> in the reduction of bacterial load of <i>Helicobacter pylori</i> and modification of gut microbiota—a double-blind, placebo-controlled, randomized trial. <i>Helicobacter</i> , 2021, 26, e12857.	1.6	18
11	Application of <i>Helicobacter pylori</i> stool antigen test to survey the updated prevalence of <i>Helicobacter pylori</i> infection in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 233-240.	1.4	9
12	Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensus. <i>Gut</i> , 2020, 69, 2093-2112.	6.1	239
13	Endoscopic submucosal dissection comparing with surgical resection in patients with early gastric cancer—A single center experience in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1750-1757.	0.8	15
14	Pandemic preparedness in Taiwan. <i>Nature Biotechnology</i> , 2020, 38, 932-933.	9.4	8
15	The Gut Metabolite Trimethylamine N-oxide Is Associated With Parkinson's Disease Severity and Progression. <i>Movement Disorders</i> , 2020, 35, 2115-2116.	2.2	30
16	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. <i>Haematologica</i> , 2020, 105, e349-e354.	1.7	5
17	Comparison of the effect of clarithromycin triple therapy with or without <i>N</i> -acetylcysteine in the eradication of <i>Helicobacter pylori</i> : a randomized controlled trial. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092730.	1.4	5
18	Effects of Vigiis 101-LAB on a healthy population's gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study. <i>Heliyon</i> , 2020, 6, e04979.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Comparison of DNA stabilizers and storage conditions on preserving fecal microbiota profiles. Journal of the Formosan Medical Association, 2020, 119, 1791-1798.	0.8	23
20	Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. Journal of the Formosan Medical Association, 2020, 119, 1626-1633.	0.8	13
21	Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1107-1116.	1.4	19
22	Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease. Journal of Neuroinflammation, 2019, 16, 129.	3.1	283
23	Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infectious Diseases, The, 2019, 19, 1109-1120.	4.6	127
24	Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter, 2019, 24, e12640.	1.6	38
25	Efficacy and Long-Term Safety of H. pylori Eradication for Gastric Cancer Prevention. Cancers, 2019, 11, 593.	1.7	36
26	From germ theory to germ therapy. Kaohsiung Journal of Medical Sciences, 2019, 35, 73-82.	0.8	6
27	IDDF2019-ABS-0213...Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after helicobacter pylori eradication- a multicentre randomised trial. , 2019, , .		0
28	IDDF2019-ABS-0126...Levofloxacin sequential therapy versus bismuth quadruple therapy in the second-line and third-line treatment of helicobacter pylori -a multicenter randomized trial. , 2019, , .		0
29	Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 59-67.	1.4	26
30	Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. Journal of Infectious Diseases, 2018, 217, 1193-1201.	1.9	67
31	First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis. Gut, 2018, 67, 20-27.	6.1	65
32	Survey of the adherence to the consensus of gastroesophageal reflux disease before and after the implementation course. Journal of the Formosan Medical Association, 2018, 117, 440-449.	0.8	3
33	Association between Helicobacter pylori infection and cognitive impairment in the elderly. Journal of the Formosan Medical Association, 2018, 117, 994-1002.	0.8	17
34	Optimization of Helicobacter pylori eradication therapies. Advances in Digestive Medicine, 2018, 5, 1-2.	0.1	0
35	A rare case of gastrocolic fistula caused by benign gastric ulcer. Advances in Digestive Medicine, 2018, 5, 142-144.	0.1	2
36	IDDF2018-ABS-0076...Optimised 14-day levofloxacin sequential versus 10-day bismuth quadruple therapy containing high dose esomeprazole in the second-line and third-line treatment of helicobacter pylori a multicenter randomised trial. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
37	Toward population specific and personalized treatment of <i>Helicobacter pylori</i> infection. <i>Journal of Biomedical Science</i> , 2018, 25, 70.	2.6	28
38	Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory <i>Helicobacter pylori</i> Infection. <i>Gastroenterology</i> , 2018, 155, 1109-1119.	0.6	66
39	Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2018, 113, 1444-1457.	0.2	28
40	The implementation of the consensus on the management of <i>Helicobacter pylori</i> and barriers to consensus. <i>Helicobacter</i> , 2018, 23, e12533.	1.6	2
41	14-day sequential therapy versus 10-day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of <i>Helicobacter pylori</i> : a multicentre, non-inferiority, randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2510-2518.	1.3	20
42	Consensus on the clinical management, screening, treat, and surveillance of <i>Helicobacter pylori</i> infection to improve gastric cancer control on a nationwide scale. <i>Helicobacter</i> , 2017, 22, e12368.	1.6	64
43	Letter: levofloxacin resistance - a challenge for treatment of <i>Helicobacter pylori</i> infection. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 573-573.	1.9	0
44	Bismuth and Non-bismuth Quadruple Therapy for <i>Helicobacter pylori</i> Eradication: Time to Make the Switch in Clinical Practice?. <i>Gastroenterology</i> , 2017, 152, 301-302.	0.6	0
45	The Impact of Gastric Atrophy on the Incidence of Diabetes. <i>Scientific Reports</i> , 2017, 7, 39777.	1.6	10
46	Expressions of the CagA protein and CagA-signaling molecules predict <i>Helicobacter pylori</i> dependence of early-stage gastric DLBCL. <i>Blood</i> , 2017, 129, 188-198.	0.6	20
47	First-line antibiotic therapy in <i>Helicobacter pylori</i> -negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. <i>Scientific Reports</i> , 2017, 7, 14333.	1.6	21
48	Primary antibiotic resistance in <i>Helicobacter pylori</i> in the Asia-Pacific region: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 707-715.	3.7	238
49	Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for <i>Helicobacter pylori</i> eradication: analysis of five randomized trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3481-3489.	1.3	23
50	Distinct Clinicopathological Features and Prognosis of <i>Helicobacter pylori</i> Negative Gastric Cancer. <i>PLoS ONE</i> , 2017, 12, e0170942.	1.1	33
51	Mass Eradication of <i>Helicobacter pylori</i> to Prevent Gastric Cancer: Theoretical and Practical Considerations. <i>Gut and Liver</i> , 2016, 10, 12.	1.4	51
52	Statins and the risk of pancreatic cancer in Type 2 diabetic patients: A population-based cohort study. <i>International Journal of Cancer</i> , 2016, 138, 594-603.	2.3	45
53	Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of <i>Helicobacter pylori</i> in the community and hospital populations: a randomised trial. <i>Gut</i> , 2016, 65, 1784-1792.	6.1	71
54	Prevention of Gastric Cancer by <i>Helicobacter pylori</i> Eradication: Current Evidence and Future Prospects. , 2016, , 181-202.		0

#	ARTICLE	IF	CITATIONS
55	Massive Left Pleural Effusion After Endoscopic Variceal Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 455.	0.2	0
56	Treatment of <i>Helicobacter pylori</i> infection: Where are we now?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1918-1926.	1.4	24
57	Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 427-437.	1.9	57
58	Reply to Kim J.S. and Kim B.-W.. <i>American Journal of Gastroenterology</i> , 2016, 111, 1497-1498.	0.2	0
59	Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. <i>Lancet, The</i> , 2016, 388, 2355-2365.	6.3	128
60	Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of <i>Helicobacter pylori</i> : A Randomized Trial. <i>American Journal of Gastroenterology</i> , 2016, 111, 381-387.	0.2	43
61	<i>Helicobacter pylori</i> CagA Translocation Is Closely Associated With the Expression of CagA-signaling Molecules in Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 761-766.	2.1	19
62	Associations of Circulating Gut Hormone and Adipocytokine Levels with the Spectrum of Gastroesophageal Reflux Disease. <i>PLoS ONE</i> , 2015, 10, e0141410.	1.1	16
63	P1-260: Relationship between <i>Helicobacter pylori</i> infection and cognitive performance in elders. , 2015, 11, P454-P454.		0
64	A Tool to Predict Risk for Gastric Cancer in Patients With Peptic Ulcer Disease on the Basis of a Nationwide Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 287-293.e1.	2.4	24
65	The Primary Resistance of <i>Helicobacter pylori</i> in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study. <i>PLoS ONE</i> , 2015, 10, e0124199.	1.1	74
66	Consensus of gastroesophageal reflux disease in Taiwan with endoscopy-based approach covered by National Health Insurance. <i>Advances in Digestive Medicine</i> , 2015, 2, 85-94.	0.1	3
67	Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria. <i>Gut</i> , 2015, 64, 1517-1528.	6.1	64
68	Comparative in vitro antimicrobial susceptibility and synergistic activity of antimicrobial combinations against <i>Helicobacter pylori</i> isolates in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 72-79.	1.5	29
69	Measurement of Visceral Fat: Should We Include Retroperitoneal Fat?. <i>PLoS ONE</i> , 2014, 9, e112355.	1.1	52
70	Predictors of in-hospital mortality after acute variceal bleeding in patients with hepatocellular carcinoma and concurrent main portal vein thrombosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 344-351.	1.4	14
71	Transcatheter Arterial Embolization with N-Butyl Cyanoacrylate for Nonvariceal Upper Gastrointestinal Bleeding in Hemodynamically Unstable Patients: Results and Predictors of Clinical Outcomes. <i>Journal of Vascular and Interventional Radiology</i> , 2014, 25, 1850-1857.	0.2	32
72	Development of bacterial transglycosylase inhibitors as new antibiotics: Moenomycin A treatment for drug-resistant <i>Helicobacter pylori</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2412-2414.	1.0	18

#	ARTICLE	IF	CITATIONS
73	Evidence-based recommendations for successful <i>Helicobacter pylori</i> treatment. Expert Review of Gastroenterology and Hepatology, 2014, 8, 21-28.	1.4	43
74	Performance of a one-step fecal sample-based test for diagnosis of <i>Helicobacter pylori</i> infection in primary care and mass screening settings. Journal of the Formosan Medical Association, 2014, 113, 899-907.	0.8	29
75	Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer. Clinica Chimica Acta, 2014, 428, 51-56.	0.5	12
76	Quadruple therapy for <i>Helicobacter pylori</i> infection – Authors' reply. Lancet, The, 2013, 381, 1459-1460.	6.3	1
77	Sequential versus triple therapy for the first-line treatment of <i>Helicobacter pylori</i> : a multicentre, open-label, randomised trial. Lancet, The, 2013, 381, 205-213.	6.3	233
78	Accuracy of faecal occult blood test and <i>Helicobacter pylori</i> stool antigen test for detection of upper gastrointestinal lesions. BMJ Open, 2013, 3, e003989.	0.8	24
79	Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory <i>Helicobacter pylori</i> infection: a multicentre clinical trial. Journal of Antimicrobial Chemotherapy, 2013, 68, 450-456.	1.3	82
80	Can clinical features stratify use of endoscopy for dyspeptic patients with high background prevalence of upper gastrointestinal cancer?. Digestive and Liver Disease, 2012, 44, 218-223.	0.4	13
81	Glycated hemoglobin A1c is superior to fasting plasma glucose as an independent risk factor for colorectal neoplasia. Cancer Causes and Control, 2012, 23, 321-328.	0.8	15
82	Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups?. Journal of Gastroenterology, 2011, 46, 183-190.	2.3	37
83	Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. International Journal of Colorectal Disease, 2011, 26, 1387-1395.	1.0	41
84	Genotypic Resistance in <i>Helicobacter pylori</i> Strains Correlates with Susceptibility Test and Treatment Outcomes after Levofloxacin- and Clarithromycin-Based Therapies. Antimicrobial Agents and Chemotherapy, 2011, 55, 1123-1129.	1.4	61
85	Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for <i>Helicobacter pylori</i> infection: a multicentre clinical trial. Journal of Antimicrobial Chemotherapy, 2011, 66, 1847-1852.	1.3	46
86	A 61-year-old man with abdominal pain for 6 months: Figure 1. Gut, 2010, 59, 147-147.	6.1	0
87	Plasma Insulin-Like Growth Factor-Binding Protein-2 Levels as Diagnostic and Prognostic Biomarker of Colorectal Cancer. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1717-1725.	1.8	71
88	Early risk stratification with simple clinical parameters for cirrhotic patients with acute upper gastrointestinal bleeding. American Journal of Emergency Medicine, 2010, 28, 884-890.	0.7	15
89	The passage of a colonic cast. Lancet, The, 2010, 375, 2099.	6.3	7
90	Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for <i>Helicobacter pylori</i> infection: a randomised comparative trial with crossover design. Gut, 2010, 59, 572-578.	6.1	100

#	ARTICLE	IF	CITATIONS
91	Psychopathology and Personality Trait in Subgroups of Functional Dyspepsia Based on Rome III Criteria. <i>American Journal of Gastroenterology</i> , 2009, 104, 2534-2542.	0.2	50
92	Delayed endoscopy as a risk factor for in-hospital mortality in cirrhotic patients with acute variceal hemorrhage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1294-1299.	1.4	63
93	Emergency endoscopy for upper gastrointestinal bleeding in patients with coronary artery disease. <i>American Journal of Emergency Medicine</i> , 2009, 27, 802-809.	0.7	11
94	Think Before or Sink After: Choosing an Appropriate NSAID by Balancing Gastrointestinal and Cardiovascular Risks. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 437-442.	0.8	2
95	The Serial Changes of Ghrelin and Leptin Levels and Their Relations to Weight Loss After Laparoscopic Minigastric Bypass Surgery. <i>Obesity Surgery</i> , 2008, 18, 84-89.	1.1	30
96	RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. <i>Journal of Gastroenterology</i> , 2008, 43, 115-123.	2.3	23
97	The Hybrid Screening Strategy Is Also Effective for Colorectal Cancer Screening in the Average-Risk Chinese Population. <i>Gastroenterology</i> , 2008, 134, 365.	0.6	0
98	Helicobacter Pylori Infection in the Elderly. <i>International Journal of Gerontology</i> , 2008, 2, 145-153.	0.7	7
99	Review: Eradication of <i>Helicobacter pylori</i> to prevent gastroduodenal diseases: Hitting more than one bird with the same stone. <i>Therapeutic Advances in Gastroenterology</i> , 2008, 1, 111-120.	1.4	16
100	Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. <i>European Journal of Cancer</i> , 2007, 43, 1276-1282.	1.3	17
101	Age and distal colonic findings determine the yield of advanced proximal neoplasia in Chinese patients with rectal bleeding. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1780-1785.	1.4	0
102	IL-1B-511 C>T Polymorphism is Associated with Increased Host Susceptibility to Helicobacter pylori Infection in Chinese. <i>Helicobacter</i> , 2007, 12, 142-149.	1.6	21
103	Screening for Colorectal Cancer in Average-Risk Chinese Population Using a Mixed Strategy with Sigmoidoscopy and Colonoscopy. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 630-640.	0.7	15
104	Jejunojejunal intussusception secondary to a jejunal lipoma in an adult. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 924-926.	1.4	8
105	Helicobacter pylori infection is not associated with increased risk of colorectal polyps in Taiwanese. <i>International Journal of Cancer</i> , 2006, 119, 1999-2000.	2.3	21
106	Comparative study of modified-release clarithromycin and immediate-release clarithromycin in the treatment of Helicobacter pylori-associated peptic ulcer disease. <i>Hepato-Gastroenterology</i> , 2006, 53, 792-6.	0.5	1
107	Typhlitis associated with Candida albicans and Pseudomonas aeruginosa infection in a patient with herbal drug-induced neutropenia. <i>Annals of Hematology</i> , 2005, 84, 689-691.	0.8	8
108	The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. <i>Gastrointestinal Endoscopy</i> , 2005, 61, 819-825.	0.5	44

#	ARTICLE	IF	CITATIONS
109	EUS features of duodenal lesions in Henoch-Schönlein purpura. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 307.	0.5	2
110	Phaeohyphomycosis caused by <i>Exophiala</i> species in immunocompromised hosts. <i>Journal of the Formosan Medical Association</i> , 2002, 101, 523-6.	0.8	13